Down-regulation of TM4SF is associated with the metastatic potential of gastric carcinoma TM4SF members in gastric carcinoma

Table 1 Relation between CD9, CD63 and CD82 expression and various prognostic factors

clinicopathological characteristics	No. of patients	CD9				CD63				CD82
		transcript		protein		transcript		protein		transcript		protein
Gender		avarage	p-value	average	p-value	avarage	p-value	average	p-value	avarage	p-value	average	p-value
Male	29	83.10	0.707	3.11	0.238	112.56	0.616	4.40	0.009	87.90	0.66	3.19	0.54
Female	20	82.31		4.06		110.12		3.00		80.47		2.64
Age
≤65	20	81.10	0.867	3.78	0.477	113.94	0.842	4.14	0.323	83.12	0.884	3.32	0.551
>65	29	83.97		3.27		109.83		3.54		86.00		2.74
Tumor stage
T1 and T2	13	85.14		3.75		114.23		3.73		91.38		4.00
T3	11	89.98	0.79	3.43	0.215	107.64	0.462	3.17	0.81	78.34	0.866	2.39	0.033
T4	15	81.97		2.17		101.82		3.54		87.85		1.81
Nodal status
N0	5	74.61		5.60		105.13		4.25		67.82		4.40
N1	13	79.73	0.556	2.91	0.03	106.47	0.774	4.23	0.028	77.85	0.23	2.88	0.094
N2	15	94.81		(N2 and N3)2,571		111.05		2.77		109.72		2.33
N3	3	86.71				114.77		6.00		64.94		1.67
metastatic status
M0	11	90.68	0.403	4.64	0.013	121.84	0.036	3.90	0.137	90.40	0.77	4.35	0
M1	18	85.46		2.17		100.24		3.19		95.17		1.23
Differentiation
G1 and G2	5	81.93		4.20		118.89		5.25		83.67		3.75
G3	24	85.77	0.82	3.05	0.624	108.33	0.432	3.31	0.105	87.57	0.691	2.23	0.304
G4	8	86.09		3.50		114.50		3.67		71.39		3.10
pTNM stage
I and II	12	79.10		4.08		109.53		3.91		73.67		4.06
III	7	105.38	0.379	3.88	0.209	112.67	0.897	2.67	0.482	106.32	0.418	3.88	0.001
IV	19	69.66		2.50		96.80		3.68		46.35		0.95
Lauren's classification
intestinal type	12	69.30	0.105	3.42	0.538	109.93	0.719	4.50	0.06	80.17	0.773	3.80	0.535
diffuse type	22	91.26		3.03		112.63		3.41		84.80		3.41

ISSN: 1477-7819